Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

Core Insights - Tevogen Bio Holdings Inc. has signed a letter of intent to lease a 17,428-square-foot facility in New Jersey to support its cell therapy manufacturing operations [2][3] - The facility, previously occupied by Pfizer and Cordis, aims to enhance Tevogen's clinical development while ensuring cost efficiency and scalability [3] - The lease term is expected to exceed five years, with occupancy anticipated after final lease execution and necessary approvals [3] Company Strategy - The new facility will be utilized for GMP cell therapy manufacturing and is expected to complement Tevogen's growing pipeline powered by its proprietary AI-driven target discovery platform, PredicTcell™ [3] - The investment in infrastructure reflects the company's commitment to delivering innovative and accessible T cell therapies, facilitating efficient scaling of manufacturing as the pipeline advances toward commercialization [4] Future Outlook - The facility is seen as a transitional step as the company plans to develop its own custom-built manufacturing facility in the future [4]